SCHOFIELD, Wis., May 18, 2009 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches, announced today that they have engaged Cannella Response Television (CRT). This is the first step in the execution of their initial go-to market strategy, which will utilize the power of a direct response television commercial to inform and educate the U.S. consumer of our organization and our powerful LipGesic M product for the relief of migraine headaches.
Cannella Response Television (http://www.drtv.com), headquartered in Burlington WI, with offices in New York and Los Angeles, specializes in television direct response media placement on national cable networks and broadcast stations. In an industry that has its share of "One-Hit Wonders," Frank Cannella (Chairman and Founder) has been in business for almost 25 years and has assembled a team that has over 75 years of Direct Response Television experience. The company has placed media for many of the industry's biggest hits and often supplements media to other agencies.
The company's primary motivation in engaging Cannella hinges on their vast breadth and depth of direct response industry knowledge. Cannella is unique in that it goes beyond the typical media placement services by adding value through a broad range of consulting services. Cannella works with clients as a project manager to guide them through the infomercial process, lending expertise to such areas as product assessment, script analysis, rough-cut evaluation, telemarketing scripting and fulfillment recommendations.
In response to this agreement, Russ Mitchell, CEO, said, "We feel fortunate to have secured an agreement with a company that can assist in the overall management of our campaign. CRT can provide the guidance necessary to make a positive difference in the execution of our Direct Response Television initiative."
In other news, PuraMed BioScience Inc. will be publishing an article on Monday, 5/18/2009, in the Wall Street Journal and the Investors Business Daily. There will be a series of articles over the next 8 weeks that are designed to educate the U.S. consumer about our company and our product offering.
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
The PuraMed BioScience Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6155